The findings reach people, from one lab or study. 11 independent labs in 8 countries; 23 trials.
“the associations between the rs2023794-C and TBS were significant in the additive (β = 0.03, P= 4.7×10−5, PFDR= 0.0003) and dominant (β = 0.032, P= 5×10−5, PFDR= 0.0003) models.”
Cells, mice and humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
11 independent labs in 8 countries
23 trials
Funders: Fondation Leducq and others
3 of 15 findings with company ties
22 of 23 trials sponsored by developers of drugs aimed at it
Human trial8
Humans28
Animals55
Cells4
In silico2
Interventions
4
Irisin
↓downin mice1
1 study
Irisin decreases SOST in mice (aged mice).
“Irisin decreased the number of osteoclasts (p = 0.0056), tartrate-resistant acid phosphatase positive (TRAP+) osteocytes (p = 0.0292), and Sost expression in the bone marrow (p = 0.026) and cortical bone (p = 0.032).”
Animalsaged mices.c.bone marrow and cortical bone100 μg/kg/weekly8 months
“elevated sclerostin can cross the blood-brain barrier, promote amyloid-β peptide deposition, and impair synaptic plasticity by suppressing Wnt/β-catenin signalling”
SOST is linked with lower estimated heel bone mineral density in humans (SOST inhibition instrumented by B4GALNT3 genetic variants) (Proxied inhibition: β-coefficient=0.034, SE = 0.007).
“The proxied SOST inhibition (instrumented by B4GALNT3 genetic variants) had a significant causal effect on increased eBMD”
HumansSOST inhibition instrumented by B4GALNT3 genetic variants
SOST impairs lipid and ceramide metabolism in mice (via adipocytic sclerostin loop3-LRP4 interaction).
“specific blockade of adipocytic sclerostin loop3-LRP4 interaction attenuates the impairment effect of sclerostin on lipid and glucose metabolism in vitro and in vivo”
“Genetically predicted higher concentrations of SOST and lower concentrations of SPP1 also conferred a higher risk of falls and lowered grip strength.”
“MR analysis also revealed a possible negative impact on bone mineral density (BMD) by genetically predicted higher levels of SOST, CCDC80, and TIMP4 (Metalloproteinase inhibitor 4).”
SOST is associated with lacunar density in young mice.
“Lacunar parameters were also affected due to Sost deletion, with altered lacunar density and volume in young mice, but these differences were not present in old mice.”
“Genetically predicted higher concentrations of SOST and lower concentrations of SPP1 also conferred a higher risk of falls and lowered grip strength.”
“genetically predicted levels of SOST (Sclerostin), CCDC80 (Coiled-coil domain-containing protein 80), NT-proBNP (N-terminal prohormone brain natriuretic peptide), and BNP (Brain natriuretic peptide) were associated with risk of hip fracture.”
SOST is associated with bone mineral density in humans (loss-of-function mutations).
“Loss-of-function mutations in SOST result in excessive bone growth, markedly increased bone density, and other skeletal abnormalities due to uncontrolled Wnt activity.”
SOST is associated with trabecular bone score in humans (β = 0.03, P= 4.7×10−5).
“the associations between the rs2023794-C and TBS were significant in the additive (β = 0.03, P= 4.7×10−5, PFDR= 0.0003) and dominant (β = 0.032, P= 5×10−5, PFDR= 0.0003) models.”
Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or…Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or heart-valve narrowing.
The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.